Study S001806

Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02456428
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 1499650
Start: 2014-03
Primary completion: 2015-05
Lead sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides
Results posted: FALSE

Registered primary outcomes

Hospitalization for incident heart failure [Patients were followed from the date of study cohort entry until hospitalization for incident heart failure, censoring, or for up to 87 months.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025972	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. Filion KB, The New England journal of medicine	2016	Randomized trial	PMID 27007958 DOI	cites ClinicalTrials.gov:NCT02456428; registry reference RESULT:27007958